Delta-Fly Pharma, Inc.
TTSE:459872.00
JPY
-3.00
(-4.00%)
Delta-Fly Pharma, Inc.
TSE:4598
(Tokyo Stock Exchange)
Recent
price
72.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.- Similar Companies
- Business
- Delta-Fly Pharma, Inc. Delta-Fly Pharma, Inc. (4598.T) develops novel anticancer drugs using proprietary module drug development technology that combines existing compounds to enhance safety and efficacy profiles. The company focuses on oncology therapeutics targeting hematologic and solid tumors, with a pipeline including DFP-10917, a nucleoside analog in phase III trials in the United States and phase I in Japan for relapsed/refractory acute myeloid leukemia; DFP-14323, a cancer stem cell regulator in phase III for lung cancer; DFP-17729 in phase I/II for solid cancers; DFP-11207, a cancer cell metabolism regulator that completed phase I for pancreatic cancer and advances in solid tumors; DFP-14927 in phase I for hematologic and solid cancers including gastroesophageal, pancreatic, and colorectal; and DFP-10825 in preclinical stages for gastric and ovarian cancers with peritoneal dissemination. Operations span Japan, Canada, China, and the United States through offices in Tokyo, Beijing, Vancouver, and ongoing international clinical programs; founded in 2010 and headquartered in Tokushima, Japan. Recent developments encompass progress updates on the phase I/II combination study of DFP-10917 with venetoclax for acute myeloid leukemia as of October 2025, advancing phase III trials for DFP-14323 in lung cancer, and multiple pipeline advancements including patient recruitment for combo trials with a mega pharmaceutical partner targeted for new drug application submission.